jfchen personal page - To The Moon

jfchen

No personal profile

1Follow

1Followers

0Topic

0Badge

2022-01-05

😞

Sorry, the original content has been removed

2022-01-05

Good 👍

Sorry, the original content has been removed

2021-06-14

Power

Sorry, the original content has been removed

2021-06-14

Yeah

Novavax says COVID-19 vaccine shows immune response against Beta virus variant

2021-06-14

Glad to hear

Vietnam approves Pfizer/BioNTech COVID-19 vaccine for emergency use

2021-06-14

Wow

Branson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public

2021-06-14

Oh no

Mortgage rates fell over the past week, despite inflation hitting a 13-year high. What's going on?

2021-06-14

To the moon

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3584267062533952,"uuid":"3584267062533952","gmtCreate":1621173084652,"gmtModify":1621173084652,"name":"jfchen","pinyin":"jfchen","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":1,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9008196229,"gmtCreate":1641381539979,"gmtModify":1676533608170,"author":{"id":"3584267062533952","authorId":"3584267062533952","name":"jfchen","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"😞","listText":"😞","text":"😞","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008196229","repostId":"1173443153","repostType":4,"isVote":1,"tweetType":1,"viewCount":156,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008196969,"gmtCreate":1641381474864,"gmtModify":1676533608155,"author":{"id":"3584267062533952","authorId":"3584267062533952","name":"jfchen","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good 👍&nbsp;","listText":"Good 👍&nbsp;","text":"Good 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008196969","repostId":"1146467548","repostType":4,"isVote":1,"tweetType":1,"viewCount":234,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185815259,"gmtCreate":1623640864071,"gmtModify":1704207604591,"author":{"id":"3584267062533952","authorId":"3584267062533952","name":"jfchen","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Power&nbsp;","listText":"Power&nbsp;","text":"Power","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/185815259","repostId":"1146430910","repostType":4,"isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182703215,"gmtCreate":1623602996137,"gmtModify":1704206883652,"author":{"id":"3584267062533952","authorId":"3584267062533952","name":"jfchen","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Yeah","listText":"Yeah","text":"Yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182703215","repostId":"2142202973","repostType":4,"repost":{"id":"2142202973","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623447457,"share":"https://www.laohu8.com/m/news/2142202973?lang=&edition=full","pubTime":"2021-06-12 05:37","market":"us","language":"en","title":"Novavax says COVID-19 vaccine shows immune response against Beta virus variant","url":"https://stock-news.laohu8.com/highlight/detail?id=2142202973","media":"Reuters","summary":"June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune respo","content":"<p>June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune response and protection against the highly contagious coronavirus variant originally identified in South Africa in a clinical trial.</p>\n<p>The vaccine, NVX-CoV2373, is being tested in multiple trials but has yet to be authorized for use in any country.</p>\n<p>Novavax also said studies in mice and baboons found that a different vaccine specifically targeting the South African variant now known as Beta produced immune response and protection, and that it expected to conduct further clinical testing of the Beta-focused vaccine in the fall.</p>\n<p>The company said testing of blood serum of thirty participants of a mid-stage trial who had received both doses of NVX-CoV2373 revealed robust antibody responses to the original version of the coronavirus as well as against the Alpha variant first found in the UK and the Beta variant.</p>\n<p>However, the response against the Beta variant was slightly less, Novavax said.</p>\n<p>The European Medicines Agency started a rolling review of the Novavax shot in February. Data from its pivotal U.S. and Mexico trial is expected to be released in the current quarter.</p>\n<p>The company said the new data is available on the online preprint server bioRxiv and has been submitted for peer review.</p>\n<p>(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli and Bill Berkrot)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax says COVID-19 vaccine shows immune response against Beta virus variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax says COVID-19 vaccine shows immune response against Beta virus variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-12 05:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune response and protection against the highly contagious coronavirus variant originally identified in South Africa in a clinical trial.</p>\n<p>The vaccine, NVX-CoV2373, is being tested in multiple trials but has yet to be authorized for use in any country.</p>\n<p>Novavax also said studies in mice and baboons found that a different vaccine specifically targeting the South African variant now known as Beta produced immune response and protection, and that it expected to conduct further clinical testing of the Beta-focused vaccine in the fall.</p>\n<p>The company said testing of blood serum of thirty participants of a mid-stage trial who had received both doses of NVX-CoV2373 revealed robust antibody responses to the original version of the coronavirus as well as against the Alpha variant first found in the UK and the Beta variant.</p>\n<p>However, the response against the Beta variant was slightly less, Novavax said.</p>\n<p>The European Medicines Agency started a rolling review of the Novavax shot in February. Data from its pivotal U.S. and Mexico trial is expected to be released in the current quarter.</p>\n<p>The company said the new data is available on the online preprint server bioRxiv and has been submitted for peer review.</p>\n<p>(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli and Bill Berkrot)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142202973","content_text":"June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune response and protection against the highly contagious coronavirus variant originally identified in South Africa in a clinical trial.\nThe vaccine, NVX-CoV2373, is being tested in multiple trials but has yet to be authorized for use in any country.\nNovavax also said studies in mice and baboons found that a different vaccine specifically targeting the South African variant now known as Beta produced immune response and protection, and that it expected to conduct further clinical testing of the Beta-focused vaccine in the fall.\nThe company said testing of blood serum of thirty participants of a mid-stage trial who had received both doses of NVX-CoV2373 revealed robust antibody responses to the original version of the coronavirus as well as against the Alpha variant first found in the UK and the Beta variant.\nHowever, the response against the Beta variant was slightly less, Novavax said.\nThe European Medicines Agency started a rolling review of the Novavax shot in February. Data from its pivotal U.S. and Mexico trial is expected to be released in the current quarter.\nThe company said the new data is available on the online preprint server bioRxiv and has been submitted for peer review.\n(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli and Bill Berkrot)","news_type":1},"isVote":1,"tweetType":1,"viewCount":93,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182477251,"gmtCreate":1623602642273,"gmtModify":1704206878961,"author":{"id":"3584267062533952","authorId":"3584267062533952","name":"jfchen","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Glad to hear","listText":"Glad to hear","text":"Glad to hear","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182477251","repostId":"2142788912","repostType":4,"repost":{"id":"2142788912","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623507814,"share":"https://www.laohu8.com/m/news/2142788912?lang=&edition=full","pubTime":"2021-06-12 22:23","market":"us","language":"en","title":"Vietnam approves Pfizer/BioNTech COVID-19 vaccine for emergency use","url":"https://stock-news.laohu8.com/highlight/detail?id=2142788912","media":"Reuters","summary":"HANOI, June 12  - Vietnam has approved the COVID-19 vaccine jointly made by Pfizer and BioNTech for domestic emergency use, the government said on Saturday.It is the fourth vaccine to be endorsed in the Southeast Asian country that is tackling a new outbreak.Vietnam, which has previously approved the AstraZeneca vaccine, Russia's Sputnik V and China's Sinopharm vaccine, said it is seeking to procure 31 million doses of the Pfizer/BioNTech version for delivery in the next quarter.Vietnam is tryin","content":"<p>HANOI, June 12 (Reuters) - Vietnam has approved the COVID-19 vaccine jointly made by Pfizer and BioNTech for domestic emergency use, the government said on Saturday.</p>\n<p>It is the fourth vaccine to be endorsed in the Southeast Asian country that is tackling a new outbreak.</p>\n<p>Vietnam, which has previously approved the AstraZeneca vaccine, Russia's Sputnik V and China's Sinopharm vaccine, said it is seeking to procure 31 million doses of the Pfizer/BioNTech version for delivery in the next quarter.</p>\n<p>Vietnam is trying to accelerate its vaccine procurement drive to tackle a more stubborn wave of infections, even though its overall case load and fatality numbers remain relatively low.</p>\n<p>The health ministry also said on Saturday it was in talks with an unidentified U.S. manufacturer to producer a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose vaccine with a view to producing 100 million-200 million shots per year.</p>\n<p>Vietnam, with a population of around 98 million, has recorded a total of 10,241 coronavirus cases, with 58 deaths, since the pandemic began. Its domestic inoculation started in March.</p>\n<p>At least 1.4 million people in Vietnam have had <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a COVID-19 vaccine, while 53,127 have been fully vaccinated, according to official data.</p>\n<p>(Reporting by Phuong Nguyen; Editing by Toby Chopra and Mike Harrison)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vietnam approves Pfizer/BioNTech COVID-19 vaccine for emergency use</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVietnam approves Pfizer/BioNTech COVID-19 vaccine for emergency use\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-12 22:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HANOI, June 12 (Reuters) - Vietnam has approved the COVID-19 vaccine jointly made by Pfizer and BioNTech for domestic emergency use, the government said on Saturday.</p>\n<p>It is the fourth vaccine to be endorsed in the Southeast Asian country that is tackling a new outbreak.</p>\n<p>Vietnam, which has previously approved the AstraZeneca vaccine, Russia's Sputnik V and China's Sinopharm vaccine, said it is seeking to procure 31 million doses of the Pfizer/BioNTech version for delivery in the next quarter.</p>\n<p>Vietnam is trying to accelerate its vaccine procurement drive to tackle a more stubborn wave of infections, even though its overall case load and fatality numbers remain relatively low.</p>\n<p>The health ministry also said on Saturday it was in talks with an unidentified U.S. manufacturer to producer a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose vaccine with a view to producing 100 million-200 million shots per year.</p>\n<p>Vietnam, with a population of around 98 million, has recorded a total of 10,241 coronavirus cases, with 58 deaths, since the pandemic began. Its domestic inoculation started in March.</p>\n<p>At least 1.4 million people in Vietnam have had <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a COVID-19 vaccine, while 53,127 have been fully vaccinated, according to official data.</p>\n<p>(Reporting by Phuong Nguyen; Editing by Toby Chopra and Mike Harrison)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142788912","content_text":"HANOI, June 12 (Reuters) - Vietnam has approved the COVID-19 vaccine jointly made by Pfizer and BioNTech for domestic emergency use, the government said on Saturday.\nIt is the fourth vaccine to be endorsed in the Southeast Asian country that is tackling a new outbreak.\nVietnam, which has previously approved the AstraZeneca vaccine, Russia's Sputnik V and China's Sinopharm vaccine, said it is seeking to procure 31 million doses of the Pfizer/BioNTech version for delivery in the next quarter.\nVietnam is trying to accelerate its vaccine procurement drive to tackle a more stubborn wave of infections, even though its overall case load and fatality numbers remain relatively low.\nThe health ministry also said on Saturday it was in talks with an unidentified U.S. manufacturer to producer a one-dose vaccine with a view to producing 100 million-200 million shots per year.\nVietnam, with a population of around 98 million, has recorded a total of 10,241 coronavirus cases, with 58 deaths, since the pandemic began. Its domestic inoculation started in March.\nAt least 1.4 million people in Vietnam have had one dose of a COVID-19 vaccine, while 53,127 have been fully vaccinated, according to official data.\n(Reporting by Phuong Nguyen; Editing by Toby Chopra and Mike Harrison)","news_type":1},"isVote":1,"tweetType":1,"viewCount":160,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182477850,"gmtCreate":1623602620370,"gmtModify":1704206878799,"author":{"id":"3584267062533952","authorId":"3584267062533952","name":"jfchen","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182477850","repostId":"1143408374","repostType":4,"repost":{"id":"1143408374","pubTimestamp":1623536483,"share":"https://www.laohu8.com/m/news/1143408374?lang=&edition=full","pubTime":"2021-06-13 06:21","market":"us","language":"en","title":"Branson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public","url":"https://stock-news.laohu8.com/highlight/detail?id=1143408374","media":"cnbc","summary":"KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, ","content":"<div>\n<p>KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC, CNBC ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Branson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBranson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-13 06:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC, CNBC ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPCE":"维珍银河"},"source_url":"https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1143408374","content_text":"KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC, CNBC confirmed on Saturday.\nThe SPAC, led by a former Goldman Sachs partner, is NextGen Acquisition II, a person familiar with the discussions told CNBC.\nA deal expected to be announced in the coming weeks, the person said.\n\nVirgin Orbit, the satellite-launching spinoff ofSir Richard Branson’sVirgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC led by a formerGoldman Sachspartner, CNBC confirmed Saturday.\nThe company is in talks on a deal withNextGen Acquisition II, a person familiar with the discussions told CNBC. NextGen II is a special purpose acquisition company led by George Mattson, who previously co-led Goldman’s global industrials group.\nSky News first reportedthe talks on Saturday, saying a deal is expected to be announced in the coming weeks. Virgin Orbit declined CNBC’s request for comment.\nThe company is a spin-off of Branson’s space tourism company Virgin Galactic.Virgin Orbit isprivately heldby Branson’s multinational conglomerate Virgin Group, with a minority stake from Abu Dhabi sovereign wealth fund Mubadala.\nVirgin Orbit uses a modified Boeing 747 aircraft to launch its rockets, a method known as air launch. Rather than launch rockets from the ground, like competitors such as Rocket Lab or Astra, the company’s aircraft carries its LauncherOne rockets up to about 45,000 feet altitude and drops them just before they fire the engine and accelerate into space –a method the company touts as more flexiblethan a ground-based system.\nLauncherOne is designed to carry small satellites that weigh up to 500 kilograms, or about 1,100 pounds,into space. Virgin Orbit completed its first successful launch in January, and plans to conduct its second later this month.\nNext Gen II raised $375 million when it completed its initial public offering in October. The funds would largely go to help Virgin Orbit scale its business. Virgin Orbit CEO Dan Hart told CNBC in October that the company was seeking to raise about $150 million in fresh capital.\nBranson took Virgin Galactic publicthrough a SPAC deal in 2019withbillionaire investor Chamath Palihapitiya.","news_type":1},"isVote":1,"tweetType":1,"viewCount":219,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182474830,"gmtCreate":1623602535720,"gmtModify":1704206877184,"author":{"id":"3584267062533952","authorId":"3584267062533952","name":"jfchen","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/182474830","repostId":"2143788716","repostType":4,"repost":{"id":"2143788716","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623527460,"share":"https://www.laohu8.com/m/news/2143788716?lang=&edition=full","pubTime":"2021-06-13 03:51","market":"hk","language":"en","title":"Mortgage rates fell over the past week, despite inflation hitting a 13-year high. What's going on?","url":"https://stock-news.laohu8.com/highlight/detail?id=2143788716","media":"Dow Jones","summary":"'The fact that rate movements don't appear to be tied to any specific data or developments makes it ","content":"<blockquote>\n 'The fact that rate movements don't appear to be tied to any specific data or developments makes it difficult to chart their path forward'.\n</blockquote>\n<p>Benchmark mortgage rates slid over the past week, without any clear reason for a decline, continuing the reprieve for price-sensitive home buyers.</p>\n<p>The 30-year fixed-rate mortgage averaged 2.96% for the week ending June 10, down three basis points from the previous week, Freddie Mac (FMCC)reported .</p>\n<p>The 15-year fixed-rate mortgage fell four basis points to an average of 2.23%. The 5-year Treasury-indexed adjustable-rate mortgage averaged 2.55%, down nine basis points from the prior week.</p>\n<p>Generally speaking, mortgage rates move roughly in tandem with long-term bond yields, including the 10-year Treasury , and this past week was not an exception.</p>\n<p>\"The Freddie Mac fixed rate for a 30-year loan dropped along with the 10-year Treasury yield this week, as investors seem to accept the Federal Reserve's view that the current inflation is temporary and a patient monetary response continues to be warranted,\" said Danielle Hale, chief economist at Realtor.com.</p>\n<p>This week's mortgage rates report could also be a reflection of the monthly jobs data released last Friday, because May's employment figures came in below expectations.</p>\n<p>Other economists, though, argued that the movement in interest rates wasn't so logical. \"The downward shift in rates, and the bond yields that influence them, has been perplexing for markets as there was not an obvious reason for such a move to occur,\" said Matthew Speakman, an economist with <a href=\"https://laohu8.com/S/Z\">Zillow</a> <a href=\"https://laohu8.com/S/ZG\">$(ZG)$</a>(ZG). He argued that the May employment figures ought to have \"merely prevented a sharp upward move in rates, rather than stoking a meaningful downturn.\"</p>\n<p>The movement in interest rates could also reflect foreign buying of U.S. Treasurys, which would put downward pressure on rates. Either way, interest rates have yet to show significant increase in keeping with the rate of inflation seen throughout the economy, which reached a 13-year high , according to the latest numbers from the consumer price index. That new data could put some upward pressure on rates.</p>\n<p>\"The fact that rate movements don't appear to be tied to any specific data or developments makes it difficult to chart their path forward in the near term,\" Speakman said.</p>\n<p>Mortgage lenders, meanwhile, are growing more pessimistic about the market's outlook. A new survey from Fannie Mae (FNMA) found that 69% of lenders expect their profit margins to decrease in the next three months, which is a record.</p>\n<p>Mortgage applications have fallen, in part because of a decline in refinancing activity as rates have risen from their record lows. But there's also evidence that demand for loans to purchase homes has fallen, which could show that buyers are being worn down by the competitive market.</p>\n<p>\"Housing bubble and crash worries are common, even showing up in a record-low share of people saying it's a good time to buy a home,\" Hale said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mortgage rates fell over the past week, despite inflation hitting a 13-year high. What's going on?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMortgage rates fell over the past week, despite inflation hitting a 13-year high. What's going on?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-13 03:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<blockquote>\n 'The fact that rate movements don't appear to be tied to any specific data or developments makes it difficult to chart their path forward'.\n</blockquote>\n<p>Benchmark mortgage rates slid over the past week, without any clear reason for a decline, continuing the reprieve for price-sensitive home buyers.</p>\n<p>The 30-year fixed-rate mortgage averaged 2.96% for the week ending June 10, down three basis points from the previous week, Freddie Mac (FMCC)reported .</p>\n<p>The 15-year fixed-rate mortgage fell four basis points to an average of 2.23%. The 5-year Treasury-indexed adjustable-rate mortgage averaged 2.55%, down nine basis points from the prior week.</p>\n<p>Generally speaking, mortgage rates move roughly in tandem with long-term bond yields, including the 10-year Treasury , and this past week was not an exception.</p>\n<p>\"The Freddie Mac fixed rate for a 30-year loan dropped along with the 10-year Treasury yield this week, as investors seem to accept the Federal Reserve's view that the current inflation is temporary and a patient monetary response continues to be warranted,\" said Danielle Hale, chief economist at Realtor.com.</p>\n<p>This week's mortgage rates report could also be a reflection of the monthly jobs data released last Friday, because May's employment figures came in below expectations.</p>\n<p>Other economists, though, argued that the movement in interest rates wasn't so logical. \"The downward shift in rates, and the bond yields that influence them, has been perplexing for markets as there was not an obvious reason for such a move to occur,\" said Matthew Speakman, an economist with <a href=\"https://laohu8.com/S/Z\">Zillow</a> <a href=\"https://laohu8.com/S/ZG\">$(ZG)$</a>(ZG). He argued that the May employment figures ought to have \"merely prevented a sharp upward move in rates, rather than stoking a meaningful downturn.\"</p>\n<p>The movement in interest rates could also reflect foreign buying of U.S. Treasurys, which would put downward pressure on rates. Either way, interest rates have yet to show significant increase in keeping with the rate of inflation seen throughout the economy, which reached a 13-year high , according to the latest numbers from the consumer price index. That new data could put some upward pressure on rates.</p>\n<p>\"The fact that rate movements don't appear to be tied to any specific data or developments makes it difficult to chart their path forward in the near term,\" Speakman said.</p>\n<p>Mortgage lenders, meanwhile, are growing more pessimistic about the market's outlook. A new survey from Fannie Mae (FNMA) found that 69% of lenders expect their profit margins to decrease in the next three months, which is a record.</p>\n<p>Mortgage applications have fallen, in part because of a decline in refinancing activity as rates have risen from their record lows. But there's also evidence that demand for loans to purchase homes has fallen, which could show that buyers are being worn down by the competitive market.</p>\n<p>\"Housing bubble and crash worries are common, even showing up in a record-low share of people saying it's a good time to buy a home,\" Hale said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"Z":"Zillow","FMCC":"房地美","ZG":"Zillow Class A","FNMA":"房利美"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143788716","content_text":"'The fact that rate movements don't appear to be tied to any specific data or developments makes it difficult to chart their path forward'.\n\nBenchmark mortgage rates slid over the past week, without any clear reason for a decline, continuing the reprieve for price-sensitive home buyers.\nThe 30-year fixed-rate mortgage averaged 2.96% for the week ending June 10, down three basis points from the previous week, Freddie Mac (FMCC)reported .\nThe 15-year fixed-rate mortgage fell four basis points to an average of 2.23%. The 5-year Treasury-indexed adjustable-rate mortgage averaged 2.55%, down nine basis points from the prior week.\nGenerally speaking, mortgage rates move roughly in tandem with long-term bond yields, including the 10-year Treasury , and this past week was not an exception.\n\"The Freddie Mac fixed rate for a 30-year loan dropped along with the 10-year Treasury yield this week, as investors seem to accept the Federal Reserve's view that the current inflation is temporary and a patient monetary response continues to be warranted,\" said Danielle Hale, chief economist at Realtor.com.\nThis week's mortgage rates report could also be a reflection of the monthly jobs data released last Friday, because May's employment figures came in below expectations.\nOther economists, though, argued that the movement in interest rates wasn't so logical. \"The downward shift in rates, and the bond yields that influence them, has been perplexing for markets as there was not an obvious reason for such a move to occur,\" said Matthew Speakman, an economist with Zillow $(ZG)$(ZG). He argued that the May employment figures ought to have \"merely prevented a sharp upward move in rates, rather than stoking a meaningful downturn.\"\nThe movement in interest rates could also reflect foreign buying of U.S. Treasurys, which would put downward pressure on rates. Either way, interest rates have yet to show significant increase in keeping with the rate of inflation seen throughout the economy, which reached a 13-year high , according to the latest numbers from the consumer price index. That new data could put some upward pressure on rates.\n\"The fact that rate movements don't appear to be tied to any specific data or developments makes it difficult to chart their path forward in the near term,\" Speakman said.\nMortgage lenders, meanwhile, are growing more pessimistic about the market's outlook. A new survey from Fannie Mae (FNMA) found that 69% of lenders expect their profit margins to decrease in the next three months, which is a record.\nMortgage applications have fallen, in part because of a decline in refinancing activity as rates have risen from their record lows. But there's also evidence that demand for loans to purchase homes has fallen, which could show that buyers are being worn down by the competitive market.\n\"Housing bubble and crash worries are common, even showing up in a record-low share of people saying it's a good time to buy a home,\" Hale said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":257,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182476333,"gmtCreate":1623602112222,"gmtModify":1704206872807,"author":{"id":"3584267062533952","authorId":"3584267062533952","name":"jfchen","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182476333","isVote":1,"tweetType":1,"viewCount":37,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9008196969,"gmtCreate":1641381474864,"gmtModify":1676533608155,"author":{"id":"3584267062533952","authorId":"3584267062533952","name":"jfchen","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good 👍&nbsp;","listText":"Good 👍&nbsp;","text":"Good 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008196969","repostId":"1146467548","repostType":4,"repost":{"id":"1146467548","pubTimestamp":1641381336,"share":"https://www.laohu8.com/m/news/1146467548?lang=&edition=full","pubTime":"2022-01-05 19:15","market":"us","language":"en","title":"Short Seller Who Bet against Wirecard Wagers Tesla is Overpriced","url":"https://stock-news.laohu8.com/highlight/detail?id=1146467548","media":"Bloomberg","summary":"Fraser Perring, the short seller who accused Wirecard AG of fraud years before the German payment pr","content":"<html><head></head><body><p>Fraser Perring, the short seller who accused Wirecard AG of fraud years before the German payment processing company’s collapse, is betting Tesla Inc.’s stratospheric valuation will come back down to earth.</p><p>The founder of Viceroy Research tweeted Wednesday that there is “price dislocation” between shares of Tesla and incumbent carmakers Toyota Motor Corp. and Volkswagen AG. The two largest auto manufacturers each sold roughly 10 or 11 vehicles for every one that Tesla delivered last year, yet the company led by Elon Musk has a $1.15 trillion market capitalization, more than double the combined valuations of Toyota and VW.</p><p>Perring was part of a team behind a 2016 report that accused Wirecard management and board members of money laundering and facilitating the evasion of U.S. restrictions on internet gambling. The company collapsed in June 2020 after revealing that 1.9 billion euros ($2.1 billion) of assets listed on its balance sheet probably never existed.</p><p>Musk, Tesla’s chief executive officer, tweeted in 2018 that short selling should be illegal and called those who take part in wagering against companies “value destroyers.” Tesla has long been one of the U.S. market’s largest shorts, which cost bears billions as the stock soared the last two years.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Short Seller Who Bet against Wirecard Wagers Tesla is Overpriced</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShort Seller Who Bet against Wirecard Wagers Tesla is Overpriced\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 19:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/short-seller-bet-against-wirecard-104556430.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Fraser Perring, the short seller who accused Wirecard AG of fraud years before the German payment processing company’s collapse, is betting Tesla Inc.’s stratospheric valuation will come back down to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/short-seller-bet-against-wirecard-104556430.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://finance.yahoo.com/news/short-seller-bet-against-wirecard-104556430.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146467548","content_text":"Fraser Perring, the short seller who accused Wirecard AG of fraud years before the German payment processing company’s collapse, is betting Tesla Inc.’s stratospheric valuation will come back down to earth.The founder of Viceroy Research tweeted Wednesday that there is “price dislocation” between shares of Tesla and incumbent carmakers Toyota Motor Corp. and Volkswagen AG. The two largest auto manufacturers each sold roughly 10 or 11 vehicles for every one that Tesla delivered last year, yet the company led by Elon Musk has a $1.15 trillion market capitalization, more than double the combined valuations of Toyota and VW.Perring was part of a team behind a 2016 report that accused Wirecard management and board members of money laundering and facilitating the evasion of U.S. restrictions on internet gambling. The company collapsed in June 2020 after revealing that 1.9 billion euros ($2.1 billion) of assets listed on its balance sheet probably never existed.Musk, Tesla’s chief executive officer, tweeted in 2018 that short selling should be illegal and called those who take part in wagering against companies “value destroyers.” Tesla has long been one of the U.S. market’s largest shorts, which cost bears billions as the stock soared the last two years.","news_type":1},"isVote":1,"tweetType":1,"viewCount":234,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185815259,"gmtCreate":1623640864071,"gmtModify":1704207604591,"author":{"id":"3584267062533952","authorId":"3584267062533952","name":"jfchen","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Power&nbsp;","listText":"Power&nbsp;","text":"Power","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/185815259","repostId":"1146430910","repostType":4,"isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008196229,"gmtCreate":1641381539979,"gmtModify":1676533608170,"author":{"id":"3584267062533952","authorId":"3584267062533952","name":"jfchen","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"😞","listText":"😞","text":"😞","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008196229","repostId":"1173443153","repostType":4,"repost":{"id":"1173443153","pubTimestamp":1641381144,"share":"https://www.laohu8.com/m/news/1173443153?lang=&edition=full","pubTime":"2022-01-05 19:12","market":"us","language":"en","title":"45 Biggest Movers from Yesterday","url":"https://stock-news.laohu8.com/highlight/detail?id=1173443153","media":"Benzinga","summary":"GainersATA Creativity Global gained 114.3% to close at $2.55.Hoth Therapeutics, Inc. surged 85.7% to","content":"<html><head></head><body><p>Gainers</p><ul><li><b>ATA Creativity Global</b> gained 114.3% to close at $2.55.</li><li><b>Hoth Therapeutics, Inc.</b> surged 85.7% to settle at $1.30 after the company announced proof-of-concept data generated using an Alzheimer&#39;s disease mouse model, supporting the therapeutic potential of HT-ALZ.</li><li><b>NexTier Oilfield Solutions Inc.</b> climbed 26.6% to settle at $4.90 on Tuesday after the company issued an operational update and guidance for the fourth quarter. The company said it expects Q4 revenue of $500-$510 million, reflecting a surge of more than 25% from Q3 2021.</li><li><b>NLS Pharmaceutics AG</b> rose 26.1% to close at $1.50 after the company announced the USPTO granted the company U.S. Patent No. 11207271, entitled A Mazindol Ir/Sr Multilayer Tablet And Its Use For The Treatment Of Attention Deficit/Hyperactivity Disorder.</li><li><b>Reliance Global Group, Inc.</b> jumped 23% to settle at $9.32.</li><li><b>REE Automotive Ltd.</b> gained 20.6% to close at $6.73.</li><li><b>Winc, Inc.</b> gained 20% to close at $6.97.</li><li><b>Oragenics, Inc.</b> climbed 18.4% to close at $0.56. The company reported in Form 4 filing that Director Robert Koski bought 1 million shares at an average price of $0.47 per share.</li><li><b>ReTo Eco-Solutions, Inc.</b> gained 18.4% to settle at $1.74 after the company announced it entered into an Equity Acquisition Agreement with Hainan REIT Mingde Investment Holding Co.</li><li><b>Arcadia Biosciences, Inc.</b> rose 17.8% to close at $1.39 on continued momentum after the company was granted a notice of allowance for a US patent titled &#39;Wheat Having Resistance to Glyphosate Due to Alterations in 5-Enol-Pyruvylshikimate-3 Phosphate Synthase.&#39;</li><li><b>NeuroBo Pharmaceuticals, Inc.</b> jumped 16.7% to close at $1.54 after gaining around 10% on Monday.</li><li><b>Plus Therapeutics, Inc.</b> surged 16.4% to close at $1.28 after the company announced it has met two significant milestones as it progresses toward cGMP manufacture of Rhenium-186 NanoLiposome.</li><li><b>eMagin Corporation</b> gained 15.5% to settle at $1.64.</li><li><b>Agrify Corporation</b> rose 15.3% to close at $11.14. Agrify announced Tuesday that it has inked a definitive agreement for its largest Agrify Total Turn-Key Solution partnership to date with Gold Leaf Florida LLC.</li><li><b>American Realty Investors, Inc.</b> surged 14.7% to close at $13.75.</li><li><b>New York City REIT, Inc.</b> gained 13.8% to settle at $12.29.</li><li><b>Immix Biopharma, Inc.</b> shares rose 12.3% to close at $6.49 on continued momentum after the U.S. Food and Drug Administration granted Rare Pediatric Disease designation for IMX-110 for the treatment of rhabdomyosarcoma, a life-threatening form of pediatric cancer in children.</li><li><b>Ford Motor Company</b> climbed 11.7% to close at $24.31 after the company announced it plans to nearly double production of the F-150 Lightning all-electric truck.</li><li><b>TherapeuticsMD, Inc.</b> gained 11.2% to close at $0.4376 after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women with vasomotor symptoms due to menopause.</li><li><b>TD Holdings, Inc.</b> rose 11.1% to close at $0.4795.</li><li><b>Heritage Insurance Holdings, Inc.</b> gained 10.9% to close at $6.53 after the company announced a $25 million buyback.</li><li><b>Reata Pharmaceuticals, Inc.</b> gained 9% to close at $29.79.</li><li><b>Aravive, Inc.</b> gained 7.4% to close at $2.63.</li><li><b>iSpecimen Inc.</b> shares gained 5.5% to close at $8.50 after Craig-Hallum initiated coverage on the stock with a Buy rating and $20 price target.</li></ul><p><b>Losers</b></p><ul><li><b>Gritstone bio, Inc.</b> dipped 42.4% to close at $7.02 as the company shared data from the first cohort (10 µg dose) of the Phase 1 booster trial of self-amplifying mRNA (samRNA) COVID-19 vaccine.</li><li><b>Zhangmen Education Inc.</b> shares fell 38.1% to close at $2.80 on Tuesday.</li><li><b>AVROBIO, Inc.</b> shares declined 36.6% to settle at $2.56 after the company reported it is shifting its portfolio priorities to focus on other clinical-stage programs and extending its cash runway into the first quarter of 2024. It is deprioritizing its Fabry disease program.</li><li><b>Heliogen, Inc.</b> fell 24.1% to settle at $10.30 after declining around 13% on Monday.</li><li><b>Valneva SE</b> fell 22.6% to close at $39.47. Valneva, last month, said its COVID-19 vaccine candidate was efficient as a booster for people who had received the same shot as an initial vaccination.</li><li><b>iCAD, Inc.</b> fell 21.4% to close at $5.88 after the company issued Q4 and FY21 sales guidance below estimates.</li><li><b>Jowell Global Ltd.</b> fell 21.2% to close at $6.93 after dipping around 60% on Monday.</li><li><b>Genprex, Inc.</b> fell 20.3% to close at $2.79. Genprex expanded gene therapy oncology pipeline to include small cell lung cancer.</li><li><b>uCloudlink Group Inc.</b> dipped 18.4% to settle at $3.10.</li><li><b>BlueCity Holdings Limited</b> dropped 16.1% to close at $1.51. BlueCity recently announced it received an acquisition offer for the company at $3.70/share.</li><li><b>Nuverra Environmental Solutions, Inc.</b> declined 15.2% to settle at $2.57.</li><li><b>Everspin Technologies, Inc.</b> shares fell 14.9% to close at $10.86.</li><li><b>ShiftPixy, Inc.</b> fell 14.4% to settle at $1.01.</li><li><b>Intra-Cellular Therapies, Inc.</b> shares dropped 14.1% to settle at $44.68 after the company reported a $400 million common stock offering.</li><li><b>Trio-Tech International</b> shares fell 14% to close at $10.70.</li><li><b>Armstrong Flooring, Inc.</b> fell 13.7% to close at $2.39. Armstrong Flooring shares climbed around 40% on Monday after the company said it is exploring a sale of the business.</li><li><b>Equillium, Inc.</b> dropped 13.3% to settle at $3.60. Equillium’s Phase 1b EQUIP study of itolizumab in patients with uncontrolled asthma met its primary objective.</li><li><b>Global-e Online Ltd.</b> shares fell 13.2% to close at $55.01.</li><li><b>Dada Nexus Limited</b> fell 13.1% to close at $11.45. Shares of Chinese companies traded lower in reaction to new Chinese cybersecurity rules from February 15.</li><li><b>Pear Therapeutics, Inc.</b> shares fell 12.2% to close at $6.70. BTIG, on Monday, initiated coverage on the stock with a Buy rating and announced a $12 price target.</li><li><b>Abcam plc</b> shares dipped 9% to close at $21.75. Alamar Biosciences and Abcam reported a strategic partnership to further understanding of the human proteome.</li></ul></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>45 Biggest Movers from Yesterday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n45 Biggest Movers from Yesterday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-05 19:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/22/01/24901630/45-biggest-movers-from-yesterday><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>GainersATA Creativity Global gained 114.3% to close at $2.55.Hoth Therapeutics, Inc. surged 85.7% to settle at $1.30 after the company announced proof-of-concept data generated using an Alzheimer's ...</p>\n\n<a href=\"https://www.benzinga.com/news/22/01/24901630/45-biggest-movers-from-yesterday\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PEAR":"Pear Therapeutics","F":"福特汽车"},"source_url":"https://www.benzinga.com/news/22/01/24901630/45-biggest-movers-from-yesterday","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173443153","content_text":"GainersATA Creativity Global gained 114.3% to close at $2.55.Hoth Therapeutics, Inc. surged 85.7% to settle at $1.30 after the company announced proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the therapeutic potential of HT-ALZ.NexTier Oilfield Solutions Inc. climbed 26.6% to settle at $4.90 on Tuesday after the company issued an operational update and guidance for the fourth quarter. The company said it expects Q4 revenue of $500-$510 million, reflecting a surge of more than 25% from Q3 2021.NLS Pharmaceutics AG rose 26.1% to close at $1.50 after the company announced the USPTO granted the company U.S. Patent No. 11207271, entitled A Mazindol Ir/Sr Multilayer Tablet And Its Use For The Treatment Of Attention Deficit/Hyperactivity Disorder.Reliance Global Group, Inc. jumped 23% to settle at $9.32.REE Automotive Ltd. gained 20.6% to close at $6.73.Winc, Inc. gained 20% to close at $6.97.Oragenics, Inc. climbed 18.4% to close at $0.56. The company reported in Form 4 filing that Director Robert Koski bought 1 million shares at an average price of $0.47 per share.ReTo Eco-Solutions, Inc. gained 18.4% to settle at $1.74 after the company announced it entered into an Equity Acquisition Agreement with Hainan REIT Mingde Investment Holding Co.Arcadia Biosciences, Inc. rose 17.8% to close at $1.39 on continued momentum after the company was granted a notice of allowance for a US patent titled 'Wheat Having Resistance to Glyphosate Due to Alterations in 5-Enol-Pyruvylshikimate-3 Phosphate Synthase.'NeuroBo Pharmaceuticals, Inc. jumped 16.7% to close at $1.54 after gaining around 10% on Monday.Plus Therapeutics, Inc. surged 16.4% to close at $1.28 after the company announced it has met two significant milestones as it progresses toward cGMP manufacture of Rhenium-186 NanoLiposome.eMagin Corporation gained 15.5% to settle at $1.64.Agrify Corporation rose 15.3% to close at $11.14. Agrify announced Tuesday that it has inked a definitive agreement for its largest Agrify Total Turn-Key Solution partnership to date with Gold Leaf Florida LLC.American Realty Investors, Inc. surged 14.7% to close at $13.75.New York City REIT, Inc. gained 13.8% to settle at $12.29.Immix Biopharma, Inc. shares rose 12.3% to close at $6.49 on continued momentum after the U.S. Food and Drug Administration granted Rare Pediatric Disease designation for IMX-110 for the treatment of rhabdomyosarcoma, a life-threatening form of pediatric cancer in children.Ford Motor Company climbed 11.7% to close at $24.31 after the company announced it plans to nearly double production of the F-150 Lightning all-electric truck.TherapeuticsMD, Inc. gained 11.2% to close at $0.4376 after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women with vasomotor symptoms due to menopause.TD Holdings, Inc. rose 11.1% to close at $0.4795.Heritage Insurance Holdings, Inc. gained 10.9% to close at $6.53 after the company announced a $25 million buyback.Reata Pharmaceuticals, Inc. gained 9% to close at $29.79.Aravive, Inc. gained 7.4% to close at $2.63.iSpecimen Inc. shares gained 5.5% to close at $8.50 after Craig-Hallum initiated coverage on the stock with a Buy rating and $20 price target.LosersGritstone bio, Inc. dipped 42.4% to close at $7.02 as the company shared data from the first cohort (10 µg dose) of the Phase 1 booster trial of self-amplifying mRNA (samRNA) COVID-19 vaccine.Zhangmen Education Inc. shares fell 38.1% to close at $2.80 on Tuesday.AVROBIO, Inc. shares declined 36.6% to settle at $2.56 after the company reported it is shifting its portfolio priorities to focus on other clinical-stage programs and extending its cash runway into the first quarter of 2024. It is deprioritizing its Fabry disease program.Heliogen, Inc. fell 24.1% to settle at $10.30 after declining around 13% on Monday.Valneva SE fell 22.6% to close at $39.47. Valneva, last month, said its COVID-19 vaccine candidate was efficient as a booster for people who had received the same shot as an initial vaccination.iCAD, Inc. fell 21.4% to close at $5.88 after the company issued Q4 and FY21 sales guidance below estimates.Jowell Global Ltd. fell 21.2% to close at $6.93 after dipping around 60% on Monday.Genprex, Inc. fell 20.3% to close at $2.79. Genprex expanded gene therapy oncology pipeline to include small cell lung cancer.uCloudlink Group Inc. dipped 18.4% to settle at $3.10.BlueCity Holdings Limited dropped 16.1% to close at $1.51. BlueCity recently announced it received an acquisition offer for the company at $3.70/share.Nuverra Environmental Solutions, Inc. declined 15.2% to settle at $2.57.Everspin Technologies, Inc. shares fell 14.9% to close at $10.86.ShiftPixy, Inc. fell 14.4% to settle at $1.01.Intra-Cellular Therapies, Inc. shares dropped 14.1% to settle at $44.68 after the company reported a $400 million common stock offering.Trio-Tech International shares fell 14% to close at $10.70.Armstrong Flooring, Inc. fell 13.7% to close at $2.39. Armstrong Flooring shares climbed around 40% on Monday after the company said it is exploring a sale of the business.Equillium, Inc. dropped 13.3% to settle at $3.60. Equillium’s Phase 1b EQUIP study of itolizumab in patients with uncontrolled asthma met its primary objective.Global-e Online Ltd. shares fell 13.2% to close at $55.01.Dada Nexus Limited fell 13.1% to close at $11.45. Shares of Chinese companies traded lower in reaction to new Chinese cybersecurity rules from February 15.Pear Therapeutics, Inc. shares fell 12.2% to close at $6.70. BTIG, on Monday, initiated coverage on the stock with a Buy rating and announced a $12 price target.Abcam plc shares dipped 9% to close at $21.75. Alamar Biosciences and Abcam reported a strategic partnership to further understanding of the human proteome.","news_type":1},"isVote":1,"tweetType":1,"viewCount":156,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182477850,"gmtCreate":1623602620370,"gmtModify":1704206878799,"author":{"id":"3584267062533952","authorId":"3584267062533952","name":"jfchen","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182477850","repostId":"1143408374","repostType":4,"repost":{"id":"1143408374","pubTimestamp":1623536483,"share":"https://www.laohu8.com/m/news/1143408374?lang=&edition=full","pubTime":"2021-06-13 06:21","market":"us","language":"en","title":"Branson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public","url":"https://stock-news.laohu8.com/highlight/detail?id=1143408374","media":"cnbc","summary":"KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, ","content":"<div>\n<p>KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC, CNBC ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Branson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBranson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-13 06:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC, CNBC ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPCE":"维珍银河"},"source_url":"https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1143408374","content_text":"KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC, CNBC confirmed on Saturday.\nThe SPAC, led by a former Goldman Sachs partner, is NextGen Acquisition II, a person familiar with the discussions told CNBC.\nA deal expected to be announced in the coming weeks, the person said.\n\nVirgin Orbit, the satellite-launching spinoff ofSir Richard Branson’sVirgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC led by a formerGoldman Sachspartner, CNBC confirmed Saturday.\nThe company is in talks on a deal withNextGen Acquisition II, a person familiar with the discussions told CNBC. NextGen II is a special purpose acquisition company led by George Mattson, who previously co-led Goldman’s global industrials group.\nSky News first reportedthe talks on Saturday, saying a deal is expected to be announced in the coming weeks. Virgin Orbit declined CNBC’s request for comment.\nThe company is a spin-off of Branson’s space tourism company Virgin Galactic.Virgin Orbit isprivately heldby Branson’s multinational conglomerate Virgin Group, with a minority stake from Abu Dhabi sovereign wealth fund Mubadala.\nVirgin Orbit uses a modified Boeing 747 aircraft to launch its rockets, a method known as air launch. Rather than launch rockets from the ground, like competitors such as Rocket Lab or Astra, the company’s aircraft carries its LauncherOne rockets up to about 45,000 feet altitude and drops them just before they fire the engine and accelerate into space –a method the company touts as more flexiblethan a ground-based system.\nLauncherOne is designed to carry small satellites that weigh up to 500 kilograms, or about 1,100 pounds,into space. Virgin Orbit completed its first successful launch in January, and plans to conduct its second later this month.\nNext Gen II raised $375 million when it completed its initial public offering in October. The funds would largely go to help Virgin Orbit scale its business. Virgin Orbit CEO Dan Hart told CNBC in October that the company was seeking to raise about $150 million in fresh capital.\nBranson took Virgin Galactic publicthrough a SPAC deal in 2019withbillionaire investor Chamath Palihapitiya.","news_type":1},"isVote":1,"tweetType":1,"viewCount":219,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182474830,"gmtCreate":1623602535720,"gmtModify":1704206877184,"author":{"id":"3584267062533952","authorId":"3584267062533952","name":"jfchen","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/182474830","repostId":"2143788716","repostType":4,"repost":{"id":"2143788716","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623527460,"share":"https://www.laohu8.com/m/news/2143788716?lang=&edition=full","pubTime":"2021-06-13 03:51","market":"us","language":"en","title":"Mortgage rates fell over the past week, despite inflation hitting a 13-year high. What's going on?","url":"https://stock-news.laohu8.com/highlight/detail?id=2143788716","media":"Dow Jones","summary":"'The fact that rate movements don't appear to be tied to any specific data or developments makes it ","content":"<blockquote>\n 'The fact that rate movements don't appear to be tied to any specific data or developments makes it difficult to chart their path forward'.\n</blockquote>\n<p>Benchmark mortgage rates slid over the past week, without any clear reason for a decline, continuing the reprieve for price-sensitive home buyers.</p>\n<p>The 30-year fixed-rate mortgage averaged 2.96% for the week ending June 10, down three basis points from the previous week, Freddie Mac (FMCC)reported .</p>\n<p>The 15-year fixed-rate mortgage fell four basis points to an average of 2.23%. The 5-year Treasury-indexed adjustable-rate mortgage averaged 2.55%, down nine basis points from the prior week.</p>\n<p>Generally speaking, mortgage rates move roughly in tandem with long-term bond yields, including the 10-year Treasury , and this past week was not an exception.</p>\n<p>\"The Freddie Mac fixed rate for a 30-year loan dropped along with the 10-year Treasury yield this week, as investors seem to accept the Federal Reserve's view that the current inflation is temporary and a patient monetary response continues to be warranted,\" said Danielle Hale, chief economist at Realtor.com.</p>\n<p>This week's mortgage rates report could also be a reflection of the monthly jobs data released last Friday, because May's employment figures came in below expectations.</p>\n<p>Other economists, though, argued that the movement in interest rates wasn't so logical. \"The downward shift in rates, and the bond yields that influence them, has been perplexing for markets as there was not an obvious reason for such a move to occur,\" said Matthew Speakman, an economist with <a href=\"https://laohu8.com/S/Z\">Zillow</a> <a href=\"https://laohu8.com/S/ZG\">$(ZG)$</a>(ZG). He argued that the May employment figures ought to have \"merely prevented a sharp upward move in rates, rather than stoking a meaningful downturn.\"</p>\n<p>The movement in interest rates could also reflect foreign buying of U.S. Treasurys, which would put downward pressure on rates. Either way, interest rates have yet to show significant increase in keeping with the rate of inflation seen throughout the economy, which reached a 13-year high , according to the latest numbers from the consumer price index. That new data could put some upward pressure on rates.</p>\n<p>\"The fact that rate movements don't appear to be tied to any specific data or developments makes it difficult to chart their path forward in the near term,\" Speakman said.</p>\n<p>Mortgage lenders, meanwhile, are growing more pessimistic about the market's outlook. A new survey from Fannie Mae (FNMA) found that 69% of lenders expect their profit margins to decrease in the next three months, which is a record.</p>\n<p>Mortgage applications have fallen, in part because of a decline in refinancing activity as rates have risen from their record lows. But there's also evidence that demand for loans to purchase homes has fallen, which could show that buyers are being worn down by the competitive market.</p>\n<p>\"Housing bubble and crash worries are common, even showing up in a record-low share of people saying it's a good time to buy a home,\" Hale said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mortgage rates fell over the past week, despite inflation hitting a 13-year high. What's going on?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMortgage rates fell over the past week, despite inflation hitting a 13-year high. What's going on?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-13 03:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<blockquote>\n 'The fact that rate movements don't appear to be tied to any specific data or developments makes it difficult to chart their path forward'.\n</blockquote>\n<p>Benchmark mortgage rates slid over the past week, without any clear reason for a decline, continuing the reprieve for price-sensitive home buyers.</p>\n<p>The 30-year fixed-rate mortgage averaged 2.96% for the week ending June 10, down three basis points from the previous week, Freddie Mac (FMCC)reported .</p>\n<p>The 15-year fixed-rate mortgage fell four basis points to an average of 2.23%. The 5-year Treasury-indexed adjustable-rate mortgage averaged 2.55%, down nine basis points from the prior week.</p>\n<p>Generally speaking, mortgage rates move roughly in tandem with long-term bond yields, including the 10-year Treasury , and this past week was not an exception.</p>\n<p>\"The Freddie Mac fixed rate for a 30-year loan dropped along with the 10-year Treasury yield this week, as investors seem to accept the Federal Reserve's view that the current inflation is temporary and a patient monetary response continues to be warranted,\" said Danielle Hale, chief economist at Realtor.com.</p>\n<p>This week's mortgage rates report could also be a reflection of the monthly jobs data released last Friday, because May's employment figures came in below expectations.</p>\n<p>Other economists, though, argued that the movement in interest rates wasn't so logical. \"The downward shift in rates, and the bond yields that influence them, has been perplexing for markets as there was not an obvious reason for such a move to occur,\" said Matthew Speakman, an economist with <a href=\"https://laohu8.com/S/Z\">Zillow</a> <a href=\"https://laohu8.com/S/ZG\">$(ZG)$</a>(ZG). He argued that the May employment figures ought to have \"merely prevented a sharp upward move in rates, rather than stoking a meaningful downturn.\"</p>\n<p>The movement in interest rates could also reflect foreign buying of U.S. Treasurys, which would put downward pressure on rates. Either way, interest rates have yet to show significant increase in keeping with the rate of inflation seen throughout the economy, which reached a 13-year high , according to the latest numbers from the consumer price index. That new data could put some upward pressure on rates.</p>\n<p>\"The fact that rate movements don't appear to be tied to any specific data or developments makes it difficult to chart their path forward in the near term,\" Speakman said.</p>\n<p>Mortgage lenders, meanwhile, are growing more pessimistic about the market's outlook. A new survey from Fannie Mae (FNMA) found that 69% of lenders expect their profit margins to decrease in the next three months, which is a record.</p>\n<p>Mortgage applications have fallen, in part because of a decline in refinancing activity as rates have risen from their record lows. But there's also evidence that demand for loans to purchase homes has fallen, which could show that buyers are being worn down by the competitive market.</p>\n<p>\"Housing bubble and crash worries are common, even showing up in a record-low share of people saying it's a good time to buy a home,\" Hale said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FMCC":"房地美","FNMA":"房利美","Z":"Zillow","ZG":"Zillow Class A"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143788716","content_text":"'The fact that rate movements don't appear to be tied to any specific data or developments makes it difficult to chart their path forward'.\n\nBenchmark mortgage rates slid over the past week, without any clear reason for a decline, continuing the reprieve for price-sensitive home buyers.\nThe 30-year fixed-rate mortgage averaged 2.96% for the week ending June 10, down three basis points from the previous week, Freddie Mac (FMCC)reported .\nThe 15-year fixed-rate mortgage fell four basis points to an average of 2.23%. The 5-year Treasury-indexed adjustable-rate mortgage averaged 2.55%, down nine basis points from the prior week.\nGenerally speaking, mortgage rates move roughly in tandem with long-term bond yields, including the 10-year Treasury , and this past week was not an exception.\n\"The Freddie Mac fixed rate for a 30-year loan dropped along with the 10-year Treasury yield this week, as investors seem to accept the Federal Reserve's view that the current inflation is temporary and a patient monetary response continues to be warranted,\" said Danielle Hale, chief economist at Realtor.com.\nThis week's mortgage rates report could also be a reflection of the monthly jobs data released last Friday, because May's employment figures came in below expectations.\nOther economists, though, argued that the movement in interest rates wasn't so logical. \"The downward shift in rates, and the bond yields that influence them, has been perplexing for markets as there was not an obvious reason for such a move to occur,\" said Matthew Speakman, an economist with Zillow $(ZG)$(ZG). He argued that the May employment figures ought to have \"merely prevented a sharp upward move in rates, rather than stoking a meaningful downturn.\"\nThe movement in interest rates could also reflect foreign buying of U.S. Treasurys, which would put downward pressure on rates. Either way, interest rates have yet to show significant increase in keeping with the rate of inflation seen throughout the economy, which reached a 13-year high , according to the latest numbers from the consumer price index. That new data could put some upward pressure on rates.\n\"The fact that rate movements don't appear to be tied to any specific data or developments makes it difficult to chart their path forward in the near term,\" Speakman said.\nMortgage lenders, meanwhile, are growing more pessimistic about the market's outlook. A new survey from Fannie Mae (FNMA) found that 69% of lenders expect their profit margins to decrease in the next three months, which is a record.\nMortgage applications have fallen, in part because of a decline in refinancing activity as rates have risen from their record lows. But there's also evidence that demand for loans to purchase homes has fallen, which could show that buyers are being worn down by the competitive market.\n\"Housing bubble and crash worries are common, even showing up in a record-low share of people saying it's a good time to buy a home,\" Hale said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":257,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182703215,"gmtCreate":1623602996137,"gmtModify":1704206883652,"author":{"id":"3584267062533952","authorId":"3584267062533952","name":"jfchen","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Yeah","listText":"Yeah","text":"Yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182703215","repostId":"2142202973","repostType":4,"repost":{"id":"2142202973","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623447457,"share":"https://www.laohu8.com/m/news/2142202973?lang=&edition=full","pubTime":"2021-06-12 05:37","market":"us","language":"en","title":"Novavax says COVID-19 vaccine shows immune response against Beta virus variant","url":"https://stock-news.laohu8.com/highlight/detail?id=2142202973","media":"Reuters","summary":"June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune respo","content":"<p>June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune response and protection against the highly contagious coronavirus variant originally identified in South Africa in a clinical trial.</p>\n<p>The vaccine, NVX-CoV2373, is being tested in multiple trials but has yet to be authorized for use in any country.</p>\n<p>Novavax also said studies in mice and baboons found that a different vaccine specifically targeting the South African variant now known as Beta produced immune response and protection, and that it expected to conduct further clinical testing of the Beta-focused vaccine in the fall.</p>\n<p>The company said testing of blood serum of thirty participants of a mid-stage trial who had received both doses of NVX-CoV2373 revealed robust antibody responses to the original version of the coronavirus as well as against the Alpha variant first found in the UK and the Beta variant.</p>\n<p>However, the response against the Beta variant was slightly less, Novavax said.</p>\n<p>The European Medicines Agency started a rolling review of the Novavax shot in February. Data from its pivotal U.S. and Mexico trial is expected to be released in the current quarter.</p>\n<p>The company said the new data is available on the online preprint server bioRxiv and has been submitted for peer review.</p>\n<p>(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli and Bill Berkrot)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax says COVID-19 vaccine shows immune response against Beta virus variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax says COVID-19 vaccine shows immune response against Beta virus variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-12 05:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune response and protection against the highly contagious coronavirus variant originally identified in South Africa in a clinical trial.</p>\n<p>The vaccine, NVX-CoV2373, is being tested in multiple trials but has yet to be authorized for use in any country.</p>\n<p>Novavax also said studies in mice and baboons found that a different vaccine specifically targeting the South African variant now known as Beta produced immune response and protection, and that it expected to conduct further clinical testing of the Beta-focused vaccine in the fall.</p>\n<p>The company said testing of blood serum of thirty participants of a mid-stage trial who had received both doses of NVX-CoV2373 revealed robust antibody responses to the original version of the coronavirus as well as against the Alpha variant first found in the UK and the Beta variant.</p>\n<p>However, the response against the Beta variant was slightly less, Novavax said.</p>\n<p>The European Medicines Agency started a rolling review of the Novavax shot in February. Data from its pivotal U.S. and Mexico trial is expected to be released in the current quarter.</p>\n<p>The company said the new data is available on the online preprint server bioRxiv and has been submitted for peer review.</p>\n<p>(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli and Bill Berkrot)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142202973","content_text":"June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune response and protection against the highly contagious coronavirus variant originally identified in South Africa in a clinical trial.\nThe vaccine, NVX-CoV2373, is being tested in multiple trials but has yet to be authorized for use in any country.\nNovavax also said studies in mice and baboons found that a different vaccine specifically targeting the South African variant now known as Beta produced immune response and protection, and that it expected to conduct further clinical testing of the Beta-focused vaccine in the fall.\nThe company said testing of blood serum of thirty participants of a mid-stage trial who had received both doses of NVX-CoV2373 revealed robust antibody responses to the original version of the coronavirus as well as against the Alpha variant first found in the UK and the Beta variant.\nHowever, the response against the Beta variant was slightly less, Novavax said.\nThe European Medicines Agency started a rolling review of the Novavax shot in February. Data from its pivotal U.S. and Mexico trial is expected to be released in the current quarter.\nThe company said the new data is available on the online preprint server bioRxiv and has been submitted for peer review.\n(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli and Bill Berkrot)","news_type":1},"isVote":1,"tweetType":1,"viewCount":93,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182477251,"gmtCreate":1623602642273,"gmtModify":1704206878961,"author":{"id":"3584267062533952","authorId":"3584267062533952","name":"jfchen","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Glad to hear","listText":"Glad to hear","text":"Glad to hear","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182477251","repostId":"2142788912","repostType":4,"repost":{"id":"2142788912","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623507814,"share":"https://www.laohu8.com/m/news/2142788912?lang=&edition=full","pubTime":"2021-06-12 22:23","market":"us","language":"en","title":"Vietnam approves Pfizer/BioNTech COVID-19 vaccine for emergency use","url":"https://stock-news.laohu8.com/highlight/detail?id=2142788912","media":"Reuters","summary":"HANOI, June 12  - Vietnam has approved the COVID-19 vaccine jointly made by Pfizer and BioNTech for domestic emergency use, the government said on Saturday.It is the fourth vaccine to be endorsed in the Southeast Asian country that is tackling a new outbreak.Vietnam, which has previously approved the AstraZeneca vaccine, Russia's Sputnik V and China's Sinopharm vaccine, said it is seeking to procure 31 million doses of the Pfizer/BioNTech version for delivery in the next quarter.Vietnam is tryin","content":"<p>HANOI, June 12 (Reuters) - Vietnam has approved the COVID-19 vaccine jointly made by Pfizer and BioNTech for domestic emergency use, the government said on Saturday.</p>\n<p>It is the fourth vaccine to be endorsed in the Southeast Asian country that is tackling a new outbreak.</p>\n<p>Vietnam, which has previously approved the AstraZeneca vaccine, Russia's Sputnik V and China's Sinopharm vaccine, said it is seeking to procure 31 million doses of the Pfizer/BioNTech version for delivery in the next quarter.</p>\n<p>Vietnam is trying to accelerate its vaccine procurement drive to tackle a more stubborn wave of infections, even though its overall case load and fatality numbers remain relatively low.</p>\n<p>The health ministry also said on Saturday it was in talks with an unidentified U.S. manufacturer to producer a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose vaccine with a view to producing 100 million-200 million shots per year.</p>\n<p>Vietnam, with a population of around 98 million, has recorded a total of 10,241 coronavirus cases, with 58 deaths, since the pandemic began. Its domestic inoculation started in March.</p>\n<p>At least 1.4 million people in Vietnam have had <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a COVID-19 vaccine, while 53,127 have been fully vaccinated, according to official data.</p>\n<p>(Reporting by Phuong Nguyen; Editing by Toby Chopra and Mike Harrison)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vietnam approves Pfizer/BioNTech COVID-19 vaccine for emergency use</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVietnam approves Pfizer/BioNTech COVID-19 vaccine for emergency use\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-12 22:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HANOI, June 12 (Reuters) - Vietnam has approved the COVID-19 vaccine jointly made by Pfizer and BioNTech for domestic emergency use, the government said on Saturday.</p>\n<p>It is the fourth vaccine to be endorsed in the Southeast Asian country that is tackling a new outbreak.</p>\n<p>Vietnam, which has previously approved the AstraZeneca vaccine, Russia's Sputnik V and China's Sinopharm vaccine, said it is seeking to procure 31 million doses of the Pfizer/BioNTech version for delivery in the next quarter.</p>\n<p>Vietnam is trying to accelerate its vaccine procurement drive to tackle a more stubborn wave of infections, even though its overall case load and fatality numbers remain relatively low.</p>\n<p>The health ministry also said on Saturday it was in talks with an unidentified U.S. manufacturer to producer a <a href=\"https://laohu8.com/S/AONE\">one</a>-dose vaccine with a view to producing 100 million-200 million shots per year.</p>\n<p>Vietnam, with a population of around 98 million, has recorded a total of 10,241 coronavirus cases, with 58 deaths, since the pandemic began. Its domestic inoculation started in March.</p>\n<p>At least 1.4 million people in Vietnam have had <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a COVID-19 vaccine, while 53,127 have been fully vaccinated, according to official data.</p>\n<p>(Reporting by Phuong Nguyen; Editing by Toby Chopra and Mike Harrison)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142788912","content_text":"HANOI, June 12 (Reuters) - Vietnam has approved the COVID-19 vaccine jointly made by Pfizer and BioNTech for domestic emergency use, the government said on Saturday.\nIt is the fourth vaccine to be endorsed in the Southeast Asian country that is tackling a new outbreak.\nVietnam, which has previously approved the AstraZeneca vaccine, Russia's Sputnik V and China's Sinopharm vaccine, said it is seeking to procure 31 million doses of the Pfizer/BioNTech version for delivery in the next quarter.\nVietnam is trying to accelerate its vaccine procurement drive to tackle a more stubborn wave of infections, even though its overall case load and fatality numbers remain relatively low.\nThe health ministry also said on Saturday it was in talks with an unidentified U.S. manufacturer to producer a one-dose vaccine with a view to producing 100 million-200 million shots per year.\nVietnam, with a population of around 98 million, has recorded a total of 10,241 coronavirus cases, with 58 deaths, since the pandemic began. Its domestic inoculation started in March.\nAt least 1.4 million people in Vietnam have had one dose of a COVID-19 vaccine, while 53,127 have been fully vaccinated, according to official data.\n(Reporting by Phuong Nguyen; Editing by Toby Chopra and Mike Harrison)","news_type":1},"isVote":1,"tweetType":1,"viewCount":160,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182476333,"gmtCreate":1623602112222,"gmtModify":1704206872807,"author":{"id":"3584267062533952","authorId":"3584267062533952","name":"jfchen","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182476333","isVote":1,"tweetType":1,"viewCount":37,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}